Search

Your search keyword '"Cohen, Alan S."' showing total 606 results
Start Over Author "Cohen, Alan S."
606 results on '"Cohen, Alan S."'

1. First Turkish Family with FAP has Homozygous Met 30 TTR

Author

Erken, Eren, Skinner, Martha, Yazici, Hasan, Dede, Hulya, Cohen, Alan S., Milunsky, Aubrey, Skare, James C., Natvig, Jacob B., editor, Førre, Øystein, editor, Husby, Gunnar, editor, Husebekk, Anne, editor, Skogen, Bjørn, editor, Sletten, Knut, editor, and Westermark, Per, editor

Published
1991
Full Text
View/download PDF

5. New USA Family has Apolipoprotein AI (ARG26) Variant

Author

Jones, Lee Anna, Harding, Jennifer A., Cohen, Alan S., Skinner, Martha, Natvig, Jacob B., editor, Førre, Øystein, editor, Husby, Gunnar, editor, Husebekk, Anne, editor, Skogen, Bjørn, editor, Sletten, Knut, editor, and Westermark, Per, editor

Published
1991
Full Text
View/download PDF

6. Isolation of a 16 KD Fraction with Extremely High AEF Activity

Author

Shirahama, Tsuranobu, Abraham, Carmela R., Ju, Shyr-Te, Miura, Katsutoshi, Cohen, Alan S., Kisilevsky, Robert, Gruys, Erik, Natvig, Jacob B., editor, Førre, Øystein, editor, Husby, Gunnar, editor, Husebekk, Anne, editor, Skogen, Bjørn, editor, Sletten, Knut, editor, and Westermark, Per, editor

Published
1991
Full Text
View/download PDF

8. Cardiac Involvement in Secondary Amyloidosis

Author

Simms, Robert W., Coats, Mary H., Skinner, Martha, Cohen, Alan S., Falk, Rodney H., Natvig, Jacob B., editor, Førre, Øystein, editor, Husby, Gunnar, editor, Husebekk, Anne, editor, Skogen, Bjørn, editor, Sletten, Knut, editor, and Westermark, Per, editor

Published
1991
Full Text
View/download PDF

29. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only

Author

Skinner, Martha, Anderson, Jennifer J., Simms, Robert, Falk, Rodney, Wang, Ming, Libbey, Caryn A., Jones, Lee Anna, and Cohen, Alan S.

Subjects
Amyloidosis -- Drug therapy, Melphalan -- Evaluation, Prednisone -- Evaluation, Colchicine -- Evaluation, Drug therapy, Combination -- Evaluation, Health, Health care industry
Abstract

PURPOSE: A clinical trial designed to test whether treatment with melphalan, prednisone, and colchicine (MPC) is superior to colchicine (C) alone was performed in patients with primary amyloidosis (AL), a nonmalignant plasma cell dyscrasia. PATIENTS AND METHODS: Patients were randomized to MPC or C with stratification according to sex, time from diagnosis to study entry (ie, less than 3 months or 3 to 12 months), and dominant organ system involvement (ie, cardiac, renal, neurologic, or other). Data were gathered monthly from patients, quarterly from physicians, and annually in the Clinical Research Center. One hundred consecutive patients with AL amyloidosis admitted between 1987 and 1992 who met eligibility requirements were treated and followed for a minimum of 18 months. Fifty patients (group A) received daily oral coichicine and 50 patients (group B) received cycles of oral melphalan and prednisone every 6 weeks for 1 year as well as colchicine. RESULTS: The principal outcome measure was median survival, which was compared in the two treatment groups and in the subgroups. The overall survival of all patients from study entry was 8.4 months. Comparing group A (C) to group B (MPC), the survival was 6.7 months versus 12.2 months (P = 0.087). Both treatment groups had poor survival for patients in the cardiac subgroup, longest survival in the renal group, and significant differences favoring MPC treatment only in patients whose major system manifestations were neurologic (P = 0.037) or other (P = 0.007). Multivariate analysis showed a strongly significant treatment effect (P = 0.003) and improved survival associated with not having cardiac or gastrointestinal involvement. CONCLUSIONS: MPC was advantageous for patients whose major manifestations of amyloid disease were other than cardiac or renal. Better survival regardless of treatment was noted in patients for whom a satisfactory supportive treatment such as transplant or dialysis exists for their organ failure.

Published
1996

39. Beta-2 Microglobulin Amyloidosis

Author

Cohen, Alan S., Shirahana, Tsuranobu, Skinner, Martha, Isobe, Takashi, editor, Araki, Shukuro, editor, Uchino, Fumiya, editor, Kito, Shozo, editor, and Tsubura, Eiro, editor

Published
1988
Full Text
View/download PDF

42. Degradation Studies on Plasma Prealbumin

Author

Skinner, Martha, Connors, Lawreen H., Kagan, Herbert M., Stone, Phillip, Cohen, Alan S., Isobe, Takashi, editor, Araki, Shukuro, editor, Uchino, Fumiya, editor, Kito, Shozo, editor, and Tsubura, Eiro, editor

Published
1988
Full Text
View/download PDF

50. Multi-paradigm modeling of mode I&II dynamic fracture mechanisms in single crystal silicon

Author

Markus Buehler., Massachusetts Institute of Technology. Dept. of Mechanical Engineering., Cohen, Alan, S. B. Massachusetts Institute of Technology, Markus Buehler., Massachusetts Institute of Technology. Dept. of Mechanical Engineering., and Cohen, Alan, S. B. Massachusetts Institute of Technology

Abstract

Thesis (S.B.)--Massachusetts Institute of Technology, Dept. of Mechanical Engineering, 2008., Includes bibliographical references (leaves 41-43)., In addition to its semi-conducting properties, silicon has the ability to be manipulated with high precision at very small length- scales. This property makes it very useful in the design of Nano/Micro-Electromechanical Systems (N/MEMS) and similar technologies. The understanding of fracture of silicon is crucial for the engineering process and the development of robust devices. However, the mechanisms of fracture in silicon are complex and are still not fully understood. Several experimental studies of fracture have been reported, however, these often lack insight into atomistic mechanisms of fracture. Ab initio computational methods (e.g. based on Density Functional Theory) to study silicon that are able to provide a fundamental description of the complex fracture mechanisms remain an open challenge. In particular, the mechanisms that lead to brittle cleavage or to the transition to ductile behavior of silicon at higher temperatures remains an open question. Empirical molecular dynamics (MD) studies have proven successful in simulating silicon fracture, but are unreliable and most models could not be validated against experimental results. Here we propose to use MD modeling based on a novel first principles reactive force fields ReaxFF, which has shown to be an accurate model to describe fracture processes of silicon. Two numerical methods are used here to study fracture mechanisms in silicon: a multi-paradigm model employing reactive and non-reactive force fields, and a fully reactive model. The CMDF and GRASP are used for the simulation of brittle fracture mechanisms in mode I and mode II loading conditions, as well as simulations of the brittle-to-ductile transition (BDT). Our results indicate that CMDF is suitable for modeling silicon brittle fracture, but has limitations during the study of the mechanisms involved in the BDT. GRASP provides a suitable framework for BDT study, and the results in this study provide for the first time an observation of the BDT w, by Alan Cohen., S.B.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results